Oxaliplatin Injection, Solution
Product Images NDC 67184-0508

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 67184-0508). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Qilu Pharmaceutical Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Oxaliplatin 01)

Chemical structure of oxaliplatin, showing the platinum (Pt) atom coordinated to a cyclohexane diamine ligand and two oxalate groups. This structural diagram illustrates key bonds and atom arrangements typical of oxaliplatin.*

FDA Label Image

Chemical Structure (Oxaliplatin 02)

A survival curve graph showing disease-free survival probability over 72 months, comparing two treatment arms: FOLFOX4 and LV5FU2. The solid line represents FOLFOX4 with 27.1% events and the dashed line LV5FU2 with 32.1% events. The graph includes hazard ratio, confidence interval, p-value, and patient numbers at risk over time.*

FDA Label Image

Figure 2 (Oxaliplatin 03)

A Kaplan-Meier survival curve graph displaying disease-free survival (DFS) probability over time in months, comparing two treatment arms: FOLFOX4 versus LV5FU2, each combined with DUKES C. The graph includes hazard ratio, confidence interval, and p-value from a logrank test for Stage III patients.*

FDA Label Image

Figure 3 (Oxaliplatin 04)

A survival curve chart comparing the percentage of patients surviving over 24 months among three treatments: Oxaliplatin Injection USP plus 5-FU/LV, Oxaliplatin Injection USP plus irinotecan, and Irinotecan plus 5-FU/LV. The chart shows median survival times with Oxaliplatin plus 5-FU/LV having the highest median survival (19.4 months), followed by Oxaliplatin plus irinotecan (17.6 months), and Irinotecan plus 5-FU/LV (14.6 months). The graph includes a statistical significance indication (p<0.0001).*

FDA Label Image

Figure 4 (Oxaliplatin 05)

Label for Oxaliplatin Injection, USP 50 mg/10 mL (5 mg/mL) single-dose vial. The sterile aqueous solution is preservative free and intended for intravenous use only. Manufactured by Qilu Pharmaceutical (Hainan) Co., Ltd., China. The label includes storage instructions, a warning about cytotoxicity, and cautions against mixing with sodium chloride or chloride-containing solutions.*

FDA Label Image

Principal Display Panel (50 mg/10 mL Carton)

Box packaging label for Oxaliplatin Injection, USP 50 mg/10 mL (5 mg/mL) intravenous solution by Qilu Pharmaceutical Co., Ltd. The label includes dosage information, use instructions for a single-dose vial, storage conditions, and cautions against mixing with sodium chloride or chloride-containing solutions. It features a barcode and space for lot and expiration dates.*

FDA Label Image

Principal Display Panel (100 mg/20 mL Carton)

Label for Oxaliplatin Injection, USP 100 mg/20 mL (5 mg/mL) intravenous solution. The label states it is a single-dose vial containing oxaliplatin 100 mg, preservative-free sterile aqueous solution, for intravenous use only, manufactured by Qilu Pharmaceutical Co., Ltd. Warnings about cytotoxicity and storage conditions are also included.*

FDA Label Image

Principal Display Panel (200 mg/40 mL Carton)

Packaging label for Oxaliplatin Injection USP 100 mg/20 mL (5 mg/mL) intravenous injection solution. The label includes usage instructions, warnings about cytotoxicity, storage conditions, and manufacturer information namely Qilu Pharmaceutical (Hainan) Co., Ltd. The design features text blocks with black and red highlights and a barcode.*

FDA Label Image

Oxaliplatin 09

Oxaliplatin Injection, USP 200 mg/40 mL (5 mg/mL) intravenous solution in a single-dose vial. The label indicates it is a sterile aqueous solution, preservative-free, for intravenous use only. Manufactured by Qilu Pharmaceutical (Hainan) Co., Ltd. The label includes handling and storage instructions and cautions about cytotoxicity.*

FDA Label Image

Oxaliplatin 10

Packaging label for Oxaliplatin Injection, USP 200 mg/40 mL (5 mg/mL) intravenous solution. The label includes usage instructions, manufacturer Qilu Pharmaceutical Co., Ltd. in Haikou, China, and a barcode. Warnings specify it contains a cytotoxic agent and must not be mixed with sodium chloride or chloride-containing solutions. The label also advises storage conditions and mentions the vial is single-dose, 40 mL.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.